Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 0.75 mg subcutaneous once weekly
DULA_SC_0p75MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.90 (-1.09 to -0.70) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.90 (-1.23 to -0.56) | 0.52 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.41 (-0.03 to 0.88) | 0.23 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.83 (-1.19 to -0.35) | 0.31 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.84 (-1.37 to -0.17) | 0.69 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.48 (-1.91 to -0.58) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.63 (-0.92 to -0.32) | 0.38 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.38 (-2.35 to 0.28) | 0.73 |
| Type 2 diabetes (adults) | HbA1c change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.03 (-1.00 to 0.99) | 0.35 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.55 (-1.24 to 0.08) | 0.28 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 0.33 (-2.01 to 3.28) | 0.29 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.22 (-1.42 to 1.04) | 0.45 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.63 (-2.66 to 1.71) | 0.21 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.20 (-3.40 to 3.32) | 0.23 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.86 (-1.73 to 0.04) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.59 (-0.83 to 2.00) | 0.09 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 64 to 130 (target week 104) | Insulin glargine | MD -2.76 (-7.59 to 2.40) | 0.49 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 6.26 (1.89 to 14.01) | 0.50 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.30 (0.12 to 0.95) | 0.17 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 2.65 (0.50 to 8.52) | 0.43 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 2.89 (0.75 to 7.85) | 0.42 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 6.80 (2.60 to 15.17) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.36 (1.62 to 16.76) | 0.59 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 15.86 (3.40 to 58.48) | 0.81 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.03 (0.59 to 21.59) | 0.60 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.22 (0.05 to 0.81) | 0.61 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.84 (0.92 to 3.75) | 0.58 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.21 (0.65 to 2.15) | 0.56 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.36 (0.08 to 1.27) | 0.74 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.68 (-2.82 to -0.59) | 0.41 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 4.18 (-0.52 to 9.09) | 0.36 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.08 (-6.14 to 4.18) | 0.34 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.75 (-11.23 to 4.51) | 0.66 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 0.39 (-3.98 to 4.91) | 0.46 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Semaglutide 3 mg oral once daily (original tablet) | MD 1.05 (-10.81 to 13.31) | 0.36 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -1.11 (-12.68 to 11.65) | 0.56 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -0.51 (-3.54 to 2.93) | 0.16 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -1.20 (-3.59 to 1.58) | 0.28 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD 0.53 (-9.11 to 9.91) | 0.23 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.42 (0.27 to 5.70) | 0.23 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.25 (0.22 to 5.69) | 0.31 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.20 (0.25 to 4.86) | 0.24 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.22 (0.25 to 4.58) | 0.23 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.12 (0.18 to 3.94) | 0.10 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.82 (0.11 to 18.75) | 0.34 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.20 (0.00 to 3.43) | 0.16 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.67 (0.09 to 14.53) | 0.37 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.18 (0.00 to 3.08) | 0.07 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.10 (0.04 to 0.35) | 0.04 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.11 (-1.65 to 1.83) | 0.50 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.33 (-0.65 to 3.29) | 0.69 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Semaglutide 3 mg oral once daily (original tablet) | MD 0.62 (-6.71 to 8.39) | 0.61 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.93 (0.75 to 1.14) | 0.53 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.19 (0.70 to 2.00) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.67 (1.31 to 2.09) | 0.67 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.30 (0.95 to 1.75) | 0.71 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.31 (1.05 to 1.64) | 0.60 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.37 (1.00 to 1.89) | 0.58 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.42 (0.06 to 2.26) | 0.77 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.14 (0.05 to 19.65) | 0.48 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.24 (0.04 to 1.12) | 0.76 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.93 (0.14 to 5.14) | 0.57 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.81 (0.05 to 11.79) | 0.50 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.29 (0.00 to 9.14) | 0.77 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.58 (0.01 to 38.31) | 0.52 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.37 (0.03 to 3.08) | 0.75 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 1.69 (0.38 to 7.63) | 0.44 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.85 (0.71 to 22.73) | 0.36 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.11 (0.26 to 4.44) | 0.61 |
Trials
- S0030901 weeks
- S0029462020 · 32 randomized · 26 weeks
- PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes2017 · 458 randomized · 52 weeks
- AWARD-PEDSA Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)2016 · 154 randomized · 26 weeks
- SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes2016 · 1,201 randomized · 40 weeks
- AWARD-10A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus2015 · 424 randomized · 24 weeks
- NCT01558271A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus2012 · 492 randomized · 52 weeks
- AWARD-7A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease2012 · 577 randomized · 52 weeks
- NCT01584232A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide2012 · 361 randomized · 26 weeks
- AWARD-CHN1The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus2012 · 737 randomized · 26 weeks
- AWARD-CHN2The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea2012 · 774 randomized · 52 weeks
- NCT01191268The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)2010 · 884 randomized · 52 weeks
- NCT01149421The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus2010 · 755 randomized · 26 weeks
- NCT01126580The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)2010 · 807 randomized · 52 weeks
- AWARD-1A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)2010 · 978 randomized · 52 weeks
- AWARD-2A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride2010 · 810 randomized · 78 weeks
- NCT01001104Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes2009 · 145 randomized · 12 weeks